Association of genetic polymorphisms of chemokines and their receptors with clearance or persistence of hepatitis C virus infection

References

• Koike K. The oncogenic role of hepatitis C virus. Recent Results Cancer Res. 2014;193:97–111.
   PubMedGoogle Scholar
• El-Bendary M, Esmat G, Neamatallah M, et al. Epidemiological aspects of intrafamilial spread of HCV infection in Egyptian population: a pilot study. Open J Gastroenterol. 2014;4(05):228.
   Google Scholar
• Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008;48:171–197.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127.
   PubMed Web of Science ®Google Scholar
• Kehrl JH. Chemoattractant receptor signaling and the control of lymphocyte migration. Immunol Res. 2006;34(3):211–227.
   PubMed Web of Science ®Google Scholar
• Mellado M, Rodríguez-Frade JM, Mañes S, et al. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 2001;19(1):397–421.
   PubMedGoogle Scholar
• Eberlein J, Nguyen TT, Victorino F, et al. Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest. 2010;120(3):907.
   PubMed Web of Science ®Google Scholar
• Fahey S, Dempsey E, Long A. The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol. 2014;11(1):25–40.
   PubMed Web of Science ®Google Scholar
• Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology. 2009;49(2):676–688.
   PubMed Web of Science ®Google Scholar
• El-Bendary M, Neamatallah M, Elalfy H, et al. The association of single nucleotide polymorphisms of Toll-like receptor 3, Toll-like receptor 7 and Toll-like receptor 8 genes with the susceptibility to HCV infection. Br J Biomed Sci. 2018;75:175–181.
   PubMed Web of Science ®Google Scholar
• El‐Bendary M, Neamatallah M, Esmat G, et al. Associations of human leucocyte antigen class II‐DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family‐based study. J Viral Hepat. 2016;23(12):961–970.
   PubMed Web of Science ®Google Scholar
• Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236.
   PubMed Web of Science ®Google Scholar
• Ruiz‐Ferrer M, Barroso N, Antinolo G, et al. Analysis of CCR5‐Δ32 and CCR2‐V64I polymorphisms in a cohort of Spanish HCV patients using real‐time polymerase chain reaction and fluorescence resonance energy transfer technologies. J Viral Hepat. 2004;11(4):319–323.
   PubMed Web of Science ®Google Scholar
• Kang W, Shin E-C. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J. 2011;52(6):871–878.
   PubMed Web of Science ®Google Scholar
• Coenen M, Nattermann J. The role of CCR5 in HCV infection. Eur J Med Res. 2010;15(3):97.
   PubMed Web of Science ®Google Scholar
• Micallef J, Kaldor J, Dore G. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41.
   PubMed Web of Science ®Google Scholar
• Attallah A, Omran D, Marie M, et al. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. B J Biomed Sci. 2018;75:157–162.
   PubMed Web of Science ®Google Scholar
• Rouhou LKC, Gorgi YL, Skhiri HA, et al. Chemokine and chemokine receptor gene polymorphism in Tunisian hemodialysis patients with HCV infection. Arab J Nephrol Transplant. 2011;4(3):117–124.
   PubMedGoogle Scholar
• Mascheretti S, Hinrichsen H, Ross S, et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C‐infected patients. Clin Exp Immunol. 2004;136(2):328–333.
   PubMed Web of Science ®Google Scholar
• Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterol. 2003;124(2):352–360.
   PubMed Web of Science ®Google Scholar
• Goulding C, Murphy A, MacDonald G, et al. The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54(8):1157–1161.
   PubMed Web of Science ®Google Scholar
• Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP‐2, with outcome of HCV infection. Hepatology. 2003;38(6):1468–1476.
   PubMed Web of Science ®Google Scholar
• Navratilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap. 2006;150(2):191–204.
   PubMedGoogle Scholar
• Heydtmann M, Shields P, McCaughan G, et al. Cytokines and chemokines in the immune response to hepatitis C infection. Curr Opin Infect Dis. 2001;14(3):279–287.
   PubMed Web of Science ®Google Scholar
• Tawadrous GA, Aziz AA, Amin DG, et al. RANTES, TNF-α, oxidative stress, and hematological abnormalities in hepatitis C virus infection. J Invest Med. 2012;60(6):878–882.
   PubMed Web of Science ®Google Scholar
• Promrat K, Liang TJ. Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? Hepatology. 2003;38(6):1359–1362.
   PubMed Web of Science ®Google Scholar
• Huik K, Avi R, Pauskar M, et al. A CCL5 haplotype is associated with low seropositivity rate of HCV infection in people who inject drugs. PLoS One. 2016;11(6):e0156850.
   PubMed Web of Science ®Google Scholar
• Berres M-L, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010;120(11):4129–4140.
   PubMed Web of Science ®Google Scholar
• Heydtmann M, Adams DH. chemokines in the immunopathogenesis of hepatitis c infection. Hepatology. 2009;49(2):676–688.
   PubMed Web of Science ®Google Scholar